Superworth

Biogen BIIB

Drug Manufacturers - General, Healthcare
$250.50
+0.60%
Market cap
$37B
PE
44.3×
10y median 16.2×
Forward PE
19.0×
10y median 14.1×
Price to sales
3.7×
EV/EBIT
39.2×
Revenue, 12 months
$10B
+0% on a year ago
Net margin
8.3%
Free cash flow yield
7.3%

Biogen trades at 44.3× trailing earnings, pricier than 99% of the last ten years. Revenue was $10B over the last twelve months, up 0% on a year earlier with a 8% net margin.

Charts

Financials

Income statement for BIIB, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$2.5B+1%$2.4B−6%$2.3B−7%$2.5B+0%$2.5B−3%$2.5B+3%$2.4B+6%$2.6B+7%$2.5B+3%$2.3B−7%$2.5B+2%$2.7B+3%
Cost of revenue$659.6M+41%$618.3M+8%$542.2M−18%$546M−8%$638.7M−3%$583.5M−6%$629.3M+16%$605M+11%$674.4M+6%$495.5M−15%$661M+5%$776.9M+28%
Gross profit$1.9B−8%$1.8B−10%$1.7B−3%$1.9B+3%$1.8B−2%$1.9B+6%$1.8B+3%$2B+6%$1.9B+2%$1.8B−5%$1.8B+1%$2B−4%
R&D$736.3M+34%$570.9M−5%$445.4M−22%$505.4M−14%$516.2M−30%$513.3M−10%$434.1M−3%$399M−21%$436.1M−16%$509.4M−1%$539M+24%$529.6M+33%
SG&A$788.2M+40%$608.5M−4%$581.5M−4%$553.8M+1%$588.4M−25%$680M+12%$572.5M−2%$583.8M+5%$594.8M+1%$682.5M+0%$607.3M+6%$709.7M+22%
$158.8M−80%$358.9M−50%$558.5M+10%$783.9M+34%$465.8M+193%$441.4M+23%$379.6M−32%$792.7M+1%$591.4M+27%$98.4M−78%$397.4M+5%$150.9M−81%
Interest expense$63.8M+7%$71.5M+31%$69.2M+11%$61.3M+25%$59.8M−6%$60M−16%$60M−13%$72.6M+18%$67.4M+13%$67.5M+13%$67.6M+13%$82.3M+13%
Pre-tax income−$141.2M$291.6M−52%$464.8M+6%$698.7M−1%$451M$291.5M+0%$311.2M−33%$744M+7%$557.3M+24%−$56M$377.7M+21%$132.4M−82%
−$72.9M$42.7M−21%$71.4M+41%$115.1M+0%$62.5M$24.8M−42%$70.7M−1%$109.2M−5%$90.8M+45%−$7.1M$58.2M−18%$34.9M−68%
Net income−$68.1M$249.7M−55%$393.4M+1%$583.6M−1%$388.5M$266.7M+7%$240.5M−39%$634.8M+9%$466.5M+20%−$48.9M$319.5M+33%$97.5M−85%
−$0.47$1.71−55%$2.70+1%$4.00−2%$2.66$1.83+7%$1.64−39%$4.33+8%$3.17+19%−$0.33$2.15+31%$0.66−85%
144.8M+0%145.9M+0%145.9M+1%145.9M+0%146.1M+1%145.6M−0%146.6M+1%146.7M+1%147.1M+1%146.8M+1%148.4M+1%148.7M+1%

Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.

Operating income: 17 periods, Q2 FY22 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 6 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 10 periods, Q4 FY08 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q3 FY26$2.6B$2.4B to $2.7B$1.99$1.81 to $2.1918
Q4 FY26$2.6B$2.5B to $2.6B$2.86$2.46 to $3.2217
Q1 FY27$2.6B$2.5B to $2.7B$3.55$2.94 to $3.929
Q2 FY27$2.7B$2.6B to $2.8B$4.16$3.89 to $4.363
Q3 FY27$2.7B$2.6B to $2.8B$4.19$3.92 to $4.383
Q4 FY27$2.7B$2.6B to $2.8B$4.08$3.82 to $4.276
Q1 FY28$2.8B$2.6B to $2.9B$4.91$4.59 to $5.148
Q2 FY28$2.8B$2.7B to $2.9B$5.39$5.04 to $5.644

Peers

Companies in Drug Manufacturers - General nearest Biogen's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BIIBBiogen$37B44.3×16.2×19.0×3.7×+0%8.3%
JAZZJazz Pharmaceuticals$13.9B14.7×20.1×n/m3.0×+13%20.4%
BMRNBiomarin Pharmaceutical$11.1B155×72.5×n/m3.3×+11%2.1%
BMYBristol-Myers Squibb$128.7B14.0×19.9×9.8×2.6×+4%18.5%
TGTXTG Therapeutics$9.2B21.9×19.6×n/m11.5×+76%55.2%
PTGXProtagonist Therapeutics$9B135×60.1×n/m32.0×+35%29.4%
CORTCorcept Therapeutics$8.7B192×28.3×n/m10.5×+16%6.6%
PFEPfizer$176B40.6×15.8×11.2×2.8×−0%6.8%
ALKSAlkermes plc.$7.5B118×16.0×n/m4.5×+11%4.0%
KNSAKiniksa Pharmaceuticals International$7.1B93.6×87.6×n/m8.4×+59%9.6%
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×n/m2.1×+9%5.0%
Peer median$9.1B67.7×24.2×10.5×3.9×+12%8.2%

More on Biogen

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .